Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Conferences

Conference Coverage

Conference Listing

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (

®). She joined AJMC® in 2013 and is the primary staff editor for 

the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for 

®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for 

Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on 

Articles

Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, biomarkers, and other cancer treatments, will be highlighted at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU).

Positive OS for Bladder Cancer Combo, Biomarkers on Tap at ASCO GU 2025

Julia is an associate editor for The American Journal of Managed Care® (AJMC®) and joined AJMC® in 2022. She produces written and video content covering multiple disease states, and assists in the screening process for manuscripts submitted to AJMC®.

She has a BA in English language and literature from Rutgers University. You can connect with Julia on 

Patients with varying stages of glaucoma saw no significant difference in outcomes between standard and enhanced monofocal intraocular lenses.

Enhanced Monofocal Lenses May Provide Alternative in Glaucoma Treatment

 in 2023, where she produces written content covering multiple disease states.

She has a BA in journalism from Seton Hall University. You can connect with Brooke on 

In an interview with The American Journal of Managed Care, Michael A. Bernstein, MD, stressed the need for effective communication and proactive screening to curb the recent tuberculosis (TB) outbreak.

Kansas City Tuberculosis Outbreak Highlights Ongoing Public Health Challenge

Cameron Santoro is an associate editor for 

), AJMC.com, and The Center for Biosimilars

Patients with mild atopic dermatitis who reported nighttime scratching experienced relief when they used an artificial intelligence (AI)-powered wearable sensor that delivered haptic feedback on sleep behaviors.

AI-Enabled Wearable Sensor Reduces Scratching in Atopic Dermatitis

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiovascular

Chronic Kidney Disease

Diabetes

Heart Failure

Type 1 Diabetes

Cardiorenalmetabolic

Alopecia

Atopic Dermatitis

Psoriasis

Dermatology

Gastroenterology

ALL/AML

CLL/SLL

GVHD

Hemophilia

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Rare Blood

Hematology

Liver

Hepatology

Autoimmune

Inflammation

Lupus

Myasthenia Gravis

Immunology

COVID-19

Vaccines

Infectious Disease

MASH

Major Depressive Disorder

Sleep

Mental Health

Duchenne Muscular Dystrophy

Epilepsy

Multiple Sclerosis

Parkinson Disease

Neurology

Obesity

Breast Cancer

Cholangiocarcinoma

Colorectal Cancer

Immuno-Oncology

Liver Cancer

Non–Small Cell Lung Cancer

Ovarian Cancer

Prostate Cancer

Skin Cancer

Small Cell Lung Cancer

Soft Tissue Sarcoma

Oncology

Ophthalmology

COPD

Pulmonary Arterial Hypertension

Pulmonology

Spinal Muscular Atrophy

Rare Disease

Asthma

Idiopathic Pulmonary Fibrosis

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Guidelines

Employers

Medicare

Reimbursement

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

View

This article provides an overview of generalized pustular psoriasis (GPP) and its clinical and economic impact, and reviews findings of Effisayil

 2, the first trial to study subcutaneous Spevigo

 (spesolimab-sbzo) in patients with GPP when not experiencing a flare.

Generalized pustular psoriasis (GPP) is a rare, severe skin condition with significant clinical and economic burdens. The Effisayil® 2 trial is the first to evaluate the efficacy of subcutaneous Spevigo® (spesolimab-sbzo) in GPP patients during non-flare periods. This study aims to provide insights into the management of GPP, potentially improving patient outcomes and reducing healthcare costs. The trial's findings could influence future treatment protocols and offer a new therapeutic option for GPP patients, addressing an unmet need in dermatological care.

Role of Spevigo® (spesolimab-sbzo) Injection in the Treatment of Generalized Pustular Psoriasis

Supplements and Featured Publications